rices are leveling, but the real story is where competitive edge is moving: from rebates and discounts to experience, trust, and the moments that keep a patient on therapy. We dig into the MFN pricing model and its ripple effects across U.S. pharma, explaining how reference-based pricing compresses margins and forces brands to compete on loyalty, adherence, and the quality of their support programs. When physicians and patients see real-time costs at the point of prescribing, “comparable” options become a head-to-head test of who delivers better help, clearer guidance, and fewer hurdles.
We walk through the new playbook for brand teams: measure what matters (six-to-twelve-month adherence, patient-initiated refills, NPS, and in-app engagement), design push moments that meet patients right when they decide to refill or speak with their doctor, and turn existing content into a living journey. Digital companions are no longer a nice-to-have—they’re loyalty infrastructure. Timely reminders, dose tracking, symptom logs, and doctor discussion guides reduce drop-offs and raise confidence. Layered on top, voice-integrated agents offer scalable, multilingual check-ins that feel personal, follow brand protocols, and escalate to humans when needed, making support available 24/7 without ballooning costs.
At the executive table, the strategy becomes both defensive and offensive. Defensively, protect market share by tightening onboarding, reducing abandonment, and integrating digital support from launch. Offensively, differentiate with patient services, bring engagement and adherence lift into payer negotiations, and broaden KPIs beyond price to lifetime value and experience metrics. As MFN pressures grow, the winners will be those who treat loyalty as a system—measured rigorously, designed intentionally, and delivered consistently. Subscribe, share this with a teammate who owns patient experience, and leave a review with the one metric you think should be on every brand dashboard.
PostScripts Rx is not intended to constitute medical advice, nor is it intended to influence prescribing decisions or any other medical or clinical decision-making. All medical and clinical judgment and decision-making, prescribing decisions, and all related considerations remain exclusively the responsibility of providers and patients.
